Retraction: Somatostatin Derivative (smsDX) Targets Cellular Metabolism in Prostate Cancer Cells after Androgen Deprivation Therapy (PLoS ONE (2013) 8:2 (e55790) DOI: 10.1371/journal.pone.0055790);Somatostatin Derivative (smsDX) Targets Cellular Metabolism in Prostate Cancer Cells after Androgen Deprivation Therapy

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Yan, Lei ^a   Xing, Zhaoquan ^a   Guo, Zhaoxin ^a   Fang, Zhiqing ^a   Jiao, Wei ^a   Guo, Xiaoyu ^b   Xu, Zhonghua ^a   Fang, Zhenghui ^b   Holmberg, Anders ^c   Nilsson, Sten ^c   Liu, Zhaoxu ^a,b,c  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN DERIVATIVE SMSDX; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CELL METABOLISM; CELL MOTILITY; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLISM; MITOCHONDRIAL FUNCTION; MITOCHONDRIAL RESPIRATION; PRENATAL PERIOD; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SWISS-PROT; TWO DIMENSIONAL GEL ELECTROPHORESIS; WOUND;

EID: 84873592453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0299822     Document Type: Erratum

References (48)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Litvinov IV, De Marzo AM, Isaacs JT, (2003) Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 88: 2972-2982.
3. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, et al. (1998) Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 95: 10820-10825.
4. Arnold JT, Isaacs JT, (2002) Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 9: 61-73.
5. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, et al. (2006) Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer 13: 151-167.
6. Volante M, Rosas R, Allia E, Granata R, Baragli A, et al. (2008) Somatostatin, cortistatin and their receptors in tumours. Mol Cell Endocrinol 286: 219-229.
7. Liu Z, Bengtsson S, Krogh M, Marquez M, Nilsson S, et al. (2007) Somatostatin effects on the proteome of the LNCaP cell-line. Int J Oncol 30: 1173-1179.
8. Hejna M, Schmidinger M, Raderer M, (2002) The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 13: 653-668.
9. Susini C, Buscail L, (2006) Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17: 1733-1742.
10. Mitsogiannis IC, Skolarikos A, Deliveliotis C, (2009) Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC). Expert Opin Pharmacother 10: 493-501.
11. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, et al. (2009) The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8: 3984-4001.
12. Cai C, Balk SP, (2011) Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 18: R175-182.
13. Talmadge JE, Fidler IJ, (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 70: 5649-5669.
14. Fidler IJ, (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3: 453-458.
15. Ward PS, Thompson CB, (2012) Signaling in control of cell growth and metabolism. Cold Spring Harb Perspect Biol 4 (7): a006783.
16. Xing Z, Zhou Z, Yu R, Li S, Li C, et al. (2010) XAF1 expression and regulatory effects of somatostatin on XAF1 in prostate cancer cells. J Exp Clin Cancer Res 29: 162.
17. Franzen B, Linder S, Okuzawa K, Kato H, Auer G, (1993) Nonenzymatic extraction of cells from clinical tumor material for analysis of gene expression by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14: 1045-1053.
18. Rabilloud T, Vuillard L, Gilly C, Lawrence JJ, (1994) Silver-staining of proteins in polyacrylamide gels: a general overview. Cell Mol Biol (Noisy-le-grand) 40: 57-75.
19. Abrahamsson PA, Lilja H, (1989) Partial characterization of a thyroid-stimulating hormone-like peptide in neuroendocrine cells of the human prostate gland. Prostate 14: 71-81.
20. Brevini TA, Bianchi R, Motta M, (1993) Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action. J Clin Endocrinol Metab 77: 626-631.
21. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P, (2011) Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2: 49.
22. Yuan TC, Veeramani S, Lin MF, (2007) Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 14: 531-547.
23. Sciarra A, Cardi A, Dattilo C, Mariotti G, Di Monaco F, et al. (2006) New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Int J Clin Pract 60: 462-470.
24. Liu Z, Marquez M, Nilsson S, Holmberg AR, (2009) Comparison of protein expression in two prostate cancer cell-lines, LNCaP and DU145, after treatment with somatostatin. Oncol Rep 22: 1451-1458.
25. Ward PS, Thompson CB, (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21: 297-308.
26. Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, et al. (2010) Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 70: 390-400.
27. Huang WC, Zhau HE, Chung LW, (2010) Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. J Biol Chem 285: 7947-7956.
28. Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, et al. (2004) Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol 92: 273-279.
29. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ, (2001) Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142: 4795-4805.
30. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, et al. (2005) The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24: 4165-4173.
31. Vander Heiden MG, Cantley LC, Thompson CB, (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
32. Raimundo N, Baysal BE, Shadel GS, (2011) Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med 17: 641-649.
33. Dang CV, (2009) PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of the Warburg effect. Sci Signal 2: pe75.
34. Wise DR, Thompson CB, (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35: 427-433.
35. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, et al. (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 105: 18782-18787.
36. Nathan C, Ding A, (2010) SnapShot: Reactive Oxygen Intermediates (ROI). Cell 140: 951-951 e952.
37. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP, (2006) DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A 103: 15091-15096.
38. Cairns RA, Harris IS, Mak TW, (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95.
39. Levine AJ, Puzio-Kuter AM, (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330 (6009): 1340-1344.
40. Pfaffenbach KT, Lee AS, (2011) The critical role of GRP78 in physiologic and pathologic stress. Curr Opin Cell Biol 23: 150-156.
41. Ni M, Zhang Y, Lee AS, (2011) Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J 434: 181-188.
42. Sun FC, Wei S, Li CW, Chang YS, Chao CC, et al. (2006) Localization of GRP78 to mitochondria under the unfolded protein response. Biochem J 396: 31-39.
43. Misra UK, Gonzalez-Gronow M, Gawdi G, Hart JP, Johnson CE, et al. (2002) The role of Grp 78 in alpha 2-macroglobulin-induced signal transduction. Evidence from RNA interference that the low density lipoprotein receptor-related protein is associated with, but not necessary for GRP78-mediated signal transduction. J Biol Chem 277: 42082-42087.
44. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, et al. (2003) Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 21: 57-63.
45. Dai RY, Chen SK, Yan DM, Chen R, Lui YP, et al. (2010) PI3K/Akt promotes GRP78 accumulation and inhibits endoplasmic reticulum stress-induced apoptosis in HEK293 cells. Folia Biol (Praha) 56: 37-46.
46. Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, et al. (2004) Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6: 275-284.
47. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, et al. (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17: 1498-1503.
48. Koutsilieris M, Tzanela M, Dimopoulos T, (1999) Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report. Prostate 38: 313-316.